Agilent Technologies and Biotrove have announced a non-exclusive reseller agreement to enable Biotrove to provide a complete solution for mass spectrometry-based drug discovery.
The agreement will combine Biotrove's Rapidfire mass spectrometry sample preparation system with Agilent's mass spectrometers.
The reseller agreement expands on an established strategic relationship between Agilent and Biotrove, furthering both companies' ability to enhance customer workflows.
The companies said that Biotrove's Rapidfire system - comprised of robotics and microfluidic handling for sample preparation and software - combined with Agilent's Triple Quadrupole and Time-of-Flight mass spectrometry instruments create a high-throughput advanced workflow solution.
The agreement includes Agilent atmospheric pressure ionisation sources with the mass spectrometers, which generate quantitative and qualitative results via sensitive and selective mass analysis, based on the molecular composition of the target compounds.
According to the companies, Rapidfire mass spectrometry decreases the bottleneck that occurs during high-throughput screening of candidate drug compounds by enabling automated sample preparation, at a rate of approximately six to eight seconds per sample, followed by seamless integration with the mass spectrometer.
Biotrove will offer complete systems comprised of its Rapidfire system combined with a broad offering of Agilent liquid chromatography-mass spectrometry (LC/MS) systems including: Agilent's 6410 Triple Quadrupole LC/MS system, its 6460 Triple Quadrupole LC/MS system with Agilent Jet Stream technology, or its 6220 Accurate Mass Time-of-Flight LC/MS system.
